Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;3(1):71-77.
doi: 10.1007/s40124-014-0065-5.

Rituximab Treatment for Nephrotic Syndrome in Children

Kazumoto Iijima  1 , Mayumi Sako  2 , Kandai Nozu  1
Affiliations

Rituximab Treatment for Nephrotic Syndrome in Children

Kazumoto Iijima et al. Curr Pediatr Rep. 2015.

Abstract

In the past 10 years, many reports have suggested that rituximab, a chimeric anti-CD20 monoclonal antibody, is effective for children with complicated, frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS). However, those reports were case reports, case series, retrospective surveys, and single-arm or short-term trials. Therefore, well-designed controlled trials are required to establish the value of rituximab in this condition. To evaluate the efficacy and safety of rituximab in childhood-onset, complicated FRNS/SDNS, a multicenter, double-blind, randomized, placebo-controlled trial was carried out by the Research Group of Childhood-onset Refractory Nephrotic Syndrome (RCRNS) in Japan (RCRNS01). RCRNS01 showed that rituximab is safe and effective for the treatment of childhood-onset, complicated FRNS/SDNS. In 2014, the use of rituximab for patients with complicated FRNS/SDNS was approved, first in the world, by the Ministry of Health, Labour and Welfare, Japan.

Keywords: Frequently relapsing; Multicenter, double-blind, randomized, placebo-controlled trial; Nephrotic syndrome; Rituximab; Steroid-dependent.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design. NS nephrotic syndrome, MMF mycophenolate mofetil, MZB mizoribine, CyA cyclosporine
See this image and copyright information in PMC

References

    1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362:629–639. doi: 10.1016/S0140-6736(03)14184-0. - DOI - PubMed
    1. Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr. 1988;113:996–1001. doi: 10.1016/S0022-3476(88)80570-5. - DOI - PubMed
    1. The Scientific Committee of the Japanese Society for Pediatric Nephrology. The 2005 Japanese Society for Pediatric Nephrology treatment guideline for idiopathic nephrotic syndrome in children. http://www.jspn.jp/pdf/0505guideline.pdf. Accessed 20 Nov 2013.
    1. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2013;10:CD002290. doi:10.1002/14651858.CD002290.pub4. - PubMed
    1. Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2010;11:CD003594. doi:10.1002/14651858.CD003594.pub4. - PubMed

LinkOut - more resources